Spreadsheet: ff51892e-1330-4dcd-9601-85ff9e4c81c6
Sheet: tab17

 | Estimated Vaccination Coverage*,† among Adolescents Aged 13-17 Years§, by Race/ethnicity¶  for Selected Vaccines  -- National Immunization Survey-Teen, United States, 2011
Vaccines | White only, non-Hispanic | Black only, non-Hispanic | Hispanic | American Indian/Alaska Native only, non-Hispanic | Asian,                           non-Hispanic
 | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.) | % (95% C.I.)
≥2 doses of MMR** | 91.4(±0.8) | 90.6(±1.9) | 90.6(±1.8) | 81.1(±11.4) | 94.6(±2.3)
[NAME] 3 doses of HepB†† | 92.8(±0.8) | 91.7(±1.7) | 91.7(±1.8) | 89.1(±5.9) | 91.9(±6.4)
Varicella
History of varicella disease§§ | 38.7(±1.3) | 31.6(±3.1) | 35.1(±3.1) | 47.6(±10.5) | 30.6(±7.4)
Among adolescents without history of disease:
≥1 dose | 92.9(±1.1) | 91.3(±2.4) | 91.0(±2.9) | 94.5(±4.2) | 93.0(±8.6)
≥2 dose | 67.3(±1.6) | 65.3(±3.7) | 71.4(±3.7) | 61.8(±13.1) | 74.8(±9.7)
History of disease or received ≥2 doses varicella vaccination | 79.9(±1.1) | 76.3(±2.8) | 81.4(±2.6) | 80.0(±7.9) | 82.5(±7.3)
Td or [NAME] since age 10 years¶¶
≥1 dose Td or [NAME] | 85.1(±1.0) | 83.1(±2.3) | 86.7(±2.2) | 80.8(±11.0) | 89.6(±4.1)
≥1 dose [NAME] | 78.6(±1.1) | 75.7(±2.7) | 78.4(±2.6) | 72.3(±11.7) | 83.8(±4.7)
≥1 dose of MenACWY*** | 68.4(±1.2) | 72.1(±2.9) | 75.3(±2.7) | 64.4(±10.9) | 76.0(±7.2)
HPV†††
FEMALE
≥1 dose | 47.5(±1.9) | 56.0(±4.7) | 65.0(±4.1) | 59.4(±11.9) | 55.8(±10.8)
≥3 doses | 33.0(±1.8) | 31.7(±4.6) | 41.6(±4.5) | 37.8(±11.5) | 35.0(±11.8)
3 dose series completion§§§ | 74.8(±2.5) | 60.8(±6.7) | 69.4(±5.5) | 71.1(±13.3) | 70.5(±15.2)
MALE
≥1 dose | 5.6(±0.8) | 10.6(±2.6) | 14.9(±3.6) | NA | NA
≥3 doses | 0.8(±0.2) | NA | 2.7(±1.3) | NA | NA
3 dose series completion§§§ | 25.9(±7.5) | NA | 29.0(±13.7) | NA | NA
 | *  Estimate presented as point estimate (%) ± 95% confidence interval (CI). Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588.
 | † Estimates with confidence intervals >20 may not be reliable.
 | § Adolescents in the 2011 NIS-Teen were born during January 1993-February 1999. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in the U.S. Virgin Islands (i.e., St. Croix, St. Thomas, and St. John) (n=484).
 | ¶  Reported by parent/guardian respondent.  Adolescents of Hispanic ethnicity may be of any race. Native Hawaiian or other Pacific Islanders and persons of multiple races were not included because of small sample sizes.
 | **  [NAME] 2 doses of measles-mumps-rubella vaccine.
 | †† ≥3 doses of hepatitis B vaccine.
 | §§By parent/guardian report or provider records.
 | ¶¶  [NAME] 1 dose of tetanus toxoid-diphtheria vaccine (Td) or tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) since the age of 10 years.
 | *** ≥1 dose of meningococcal conjugate vaccine or meningococcal -unknown type vaccine.
 | ††† ≥1dose of human papillomavirus vaccine, either quadrivalent or bivalent. Percentages reported among females (n=11,236) and males (n=12,328). Some adolescents may have received more than the three recommended HPV doses.
 | §§§ Percent of males or females who received three doses among those who had at least one HPV dose and at least 24 weeks between the first dose and the interview date.